Alteration of GLIS3 gene expression pattern in patients with breast cancer

Authors
Farzaneh Rami 1
Azar Baradaran 2
Mahboobeh Mojaver Kahnamooi 1
Mansoor Salehi 1
1 Department of Biology, Molecular Genetics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: The GLIS family members are zinc fingers with transcriptional repression and activation function. GLIS3 is one of these family members, which aberrant expression of it revealed to be related to several different cancer types. Regarding to the role of GLIS3 in tumor genesis and its probable connection with β-catenin signaling pathway, one of the pathways that involves in both normal development and tumor genesis of breast tissue, the aim of this study is investigating the alteration of GLIS3 mRNA expression level in breast cancer.
Materials and Methods: Real-time polymerase chain reaction performed with GLIS3 and GAPDH genes primer on the RNA which extracted from 15 fresh frozen breast tumor tissue samples and also 15 normal samples with slight distance from site of tumor.




Results: The relative expression of GLIS3 in breast cancer tissues revealed a 4 times increase comparing normal breast tissues; with a significant difference between cancer and normal samples (P = 0.027) and in patients without lymph node involvement and tissues that had estrogen receptor (ER−) and progesterone receptor (PR−) statuses. We see no significant difference between cancer and normal tissues based on lobular or ductal origin of the tumor as well as the tumor grade.
Conclusions: Our study suggested a probable relationship between GLIS3 overexpression and breast cancer. Furthermore, detection of a probable association between GLIS3 overexpression and triple-negative breast cancer (ER−/PR−/human epidermal growth factor receptor 2−) might be useful for prognostic and diagnostic uses or as a probable target for treatment of these patients.

Keywords

1.
King TD, Suto MJ, Li Y. The Wnt/ß-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012;113:13-8.  Back to cited text no. 1
    
2.
Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010;119:601-12.  Back to cited text no. 2
    
3.
Cancer: WHO Media Centre; Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. [Last accessed on 2014 February 28].  Back to cited text no. 3
    
4.
Khazaee-pool M, Majlessi F, Foroushani AR, Montazeri A, Nedjat S, Shojaeizadeh D, et al. Perception of breast cancer screening among Iranian women without experience of mammography: A qualitative study. Asian Pac J Cancer Prev 2014;15:3965-71.  Back to cited text no. 4
    
5.
institue nc. Genetics of Breast and Ovarian Cancer (PDQ ®): National Institue of Health. Available from: http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional. [Last accessed on 2014 February 28].  Back to cited text no. 5
    
6.
Kobayashi H, Ohno S, Sasaki Y, Matsuura M. Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 2013;30:1019-29.  Back to cited text no. 6
    
7.
Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: Interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 2011;13:211.  Back to cited text no. 7
    
8.
Al Saleh S, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 2011;38:1197-217.  Back to cited text no. 8
    
9.
MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009;17:9-26.  Back to cited text no. 9
    
10.
Prosperi JR, Goss KH. A Wnt-ow of opportunity: Targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 2010;11:1074-88.  Back to cited text no. 10
    
11.
Lichti-Kaiser K, ZeRuth G, Kang HS, Vasanth S, Jetten AM. Gli-similar proteins: Their mechanisms of action, physiological functions, and roles in disease. Vitam Horm 2012;88:141-71.  Back to cited text no. 11
    
12.
Song W, Chen YP, Huang R, Chen K, Pan PL, Li J, et al. GLIS1 rs797906: An increased risk factor for late-onset Parkinson's disease in the Han Chinese population. Eur Neurol 2012;68:89-92.  Back to cited text no. 12
    
13.
Dimitri P, Warner JT, Minton JA, Patch AM, Ellard S, Hattersley AT, et al. Novel GLIS3 mutations demonstrate an extended multisystem phenotype. Eur J Endocrinol 2011;164:437-43.  Back to cited text no. 13
    
14.
Senée V, Chelala C, Duchatelet S, Feng D, Blanc H, Cossec JC, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 2006;38:682-7.  Back to cited text no. 14
    
15.
Yang Y, Chang BH, Samson SL, Li MV, Chan L. The Krüppel-like zinc finger protein GLIS3 directly and indirectly activates insulin gene transcription. Nucleic Acids Res 2009;37:2529-38.  Back to cited text no. 15
    
16.
Kang HS, ZeRuth G, Lichti-Kaiser K, Vasanth S, Yin Z, Kim YS, et al. Gli-similar (Glis) Krüppel-like zinc finger proteins: Insights into their physiological functions and critical roles in neonatal diabetes and cystic renal disease. Histol Histopathol 2010;25:1481-96.  Back to cited text no. 16
    
17.
Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007;113:325-37.  Back to cited text no. 17
    
18.
Yusenko MV, Kovacs G. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma. Histopathology 2009;55:687-95.  Back to cited text no. 18
    
19.
Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5:e12548.  Back to cited text no. 19
    
20.
ZeRuth GT, Yang XP, Jetten AM. Modulation of the transactivation function and stability of Krüppel-like zinc finger protein Gli-similar 3 (GLIS3) by Suppressor of Fused. J Biol Chem 2011;286:22077-89.  Back to cited text no. 20
    
21.
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.  Back to cited text no. 21
    
22.
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012;38:698-707.  Back to cited text no. 22
    
23.
García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance. Int J Mol Sci 2012;14:108-45.  Back to cited text no. 23
    
24.
King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal 2012;24:846-51.  Back to cited text no. 24
    
25.
ZeRuth GT, Takeda Y, Jetten AM. The Krüppel-like protein Gli-similar 3 (GLIS3) functions as a key regulator of insulin transcription. Mol Endocrinol 2013;27:1692-705.  Back to cited text no. 25
    
26.
Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities. Oncologist 2014;19:805-13.  Back to cited text no. 26
    
27.
Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. Breast. AJCC Cancer Staging Atlas: A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook. 2nd ed. New York, NY: Springer; 2012. p. 419.  Back to cited text no. 27
Advanced Biomedical Research
Volume 2016, March
March 2016
Pages 1-5